Cancer Research Annual Meeting 2010 Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garcia, M.
Right arrow Articles by Rio, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garcia, M.
Right arrow Articles by Rio, M. D.
[Cancer Research 64, 5632-5642, August 15, 2004]
© 2004 American Association for Cancer Research

Regular Articles

Inhibition of Xenografted Human Melanoma Growth and Prevention of Metastasis Development by Dual Antiangiogenic/Antitumor Activities of Pigment Epithelium-Derived Factor

Marta Garcia1, Nuria Isabel Fernandez-Garcia2, Veronica Rivas2, Marta Carretero1, Maria J. Escamez1, Alicia Gonzalez-Martin2, Estela E. Medrano3, Olga Volpert4, Jose L. Jorcano1, Benilde Jimenez2, Fernando Larcher1 and Marcela Del Rio1

1 Project on Damage, Repair and Tissue Engineering CIEMAT and Fundación M. Botin, Madrid, Spain; 2 Department of Biochemistry, Universidad Autónoma de Madrid-Instituto de Investigaciones Biomédicas CSIC-UAM, Madrid, Spain; 3 Department of Molecular and Cellular Biology and Dermatology, Huffington Center on Aging, Baylor College of Medicine, Houston, Texas; and 4 Northwestern University Medical School, Department of Urology, Chicago, Illinois


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Human melanoma mortality is associated with the growth of metastasis in selected organs including the lungs, liver, and brain. In this study, we examined the consequences of overexpression of pigment epithelium-derived factor (PEDF), a neurotrophic factor and potent angiogenesis inhibitor, on both melanoma primary tumor growth and metastasis development. PEDF overexpression by melanoma cells greatly inhibited subcutaneous tumor formation and completely prevented lung and liver metastasis in immunocompromised mice after tail vein injection of metastatic human melanoma cell lines. Whereas the effects of PEDF on primary tumor xenografts appear mostly associated with inhibition of the angiogenic tumor response, abrogation of melanoma metastasis appears to depend on direct PEDF effects on both migration and survival of melanoma cells. PEDF-mediated inhibition of melanoma metastases could thus have a major impact on existing therapies for melanoma.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The incidence of melanoma has increased steadily during the last decades. The latest epidemiology data indicate that in the United States, around 50,000 new cases will be diagnosed (and almost 10,000 of them will have a lethal outcome) within a year’s time (1) . The high mortality rates associated with advanced melanoma rely on the metastatic dissemination of tumor cells from their primary sites and generation of chemoresistance as a consequence of alteration of key molecules involved in the regulation of cell survival (2, 3, 4) . Thus far, systemic therapies for metastatic cutaneous melanoma, the most aggressive of all skin cancers, have proven disappointing. Use of modifiers of biological responses, alone or in combination with chemotherapy, aim at improving and building more durable responses. Among such modifiers, those targeting the metastasis-host tissue interactions, including antiangiogenic factors, remain promising therapeutic agents (5, 6, 7) . Pigment epithelium-derived factor (PEDF), initially identified as neuronal differentiation factor produced by cultured human retinal pigment epithelial cells (8) , has recently been shown to be a potent inhibitor of angiogenesis in the eye by inducing apoptosis in actively dividing endothelial cells (9) . Conversely, however, PEDF has also been shown to promote the survival of certain neurons. The potential role of PEDF as an antiangiogenic agent in the context of solid tumors has recently begun to be explored, pointing to a more widespread angioinhibitory role for this multifunctional factor (10, 11, 12) . Studies in PEDF knockout mice showed increased vessel density in several organs, combined with marked hyperplasia of the pancreas and prostate epithelium. Moreover, highly tumorigenic prostate cell lines showed reduced PEDF expression compared with less tumorigenic ones. Thus, it is likely that PEDF has an inhibitory effect on prostate tumor development (13) .

In this study, we present evidence for a dramatic effect of PEDF on the growth of primary melanoma and metastases. We observed both a canonical antiangiogenic effect of PEDF, consistent with previous reports, and a newly discovered direct effect of PEDF on melanoma cells. Our results emphasize that PEDF is targeting both the tumor and tumor vasculature, leading to a more efficient blockade of tumor growth than that achieved by using purely antiangiogenic compounds aimed exclusively at destroying the tumor vasculature.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cells.
Human umbilical vascular endothelial cells were obtained from umbilical cords as described previously (14) and cultured in M199 (Sigma, St. Louis, MO) supplemented with 20% fetal calf serum (FCS), 50 µg/ml endothelial cell growth supplement from bovine brain, 0.1 mg/ml heparin, and 1% antibiotic-antimycotic (GIBCO) in tissue culture flasks precoated with 0.5% gelatin. Cells between passages 4 and 6 were used for migration assays. Human melanoma cell line UCD-Mel-N was derived from a patient with multiple primary melanoma tumors (15 , 16) . The packaging cell line PA317 was obtained from American Type Culture Collection. BAEC, UCD-Mel-N, and PA317 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; GIBCO-BRL) supplemented with 10% FCS and 1% antibiotic-antimycotic (GIBCO). Cells were cultured at 37°C in a humid atmosphere containing 5% CO2.

Retroviral Vector Design and Production.
Retroviral expression vectors were constructed using the LZRS backbone vector (17 , 18) . The human PEDF cDNA (a gift from Dr. Noel Bouck) was cloned into pLZRS-IRES-EGFP vector plasmid (19) . Defective retroviruses were generated through transient transfection of 293T cells with packaging and retroviral vector plasmids (18) .

Generation of a Stable Retroviral Packaging Cell Line: PA317-EGFP+ and PA317-PEDF-IRES-EGFP.
The packaging cell line PA317 (American Type Culture Collection) was used to generate a stable cell line to produce amphotropic retroviral particles containing the pLZR-IRES-EGFP or pLZRS-PEDF-IRES-EGFP sequence. The sequence was integrated in the PA317 genome by infection with ecotropic particles obtained from transient transfection in 293T cells (American Type Culture Collection). Briefly, 293T cells were seeded into 3 ml of D-10 media in 60-mm dishes at 2 x 106 cells/dish and transfected the following day in fresh medium containing 25 mM chloroquine. 293T cells were cotransfected with 5 µg of a packaging vector and 5 µg of the pLZR-IRES-EGFP or pLZR-PEDF-IRES-EGFP using calcium phosphate for 8 h. First and second retroviral 12-h supernatants from 293T cells were recovered at the moment of infection and filtered through a 45-µm filter. The supernatants were added together with 8 µg/ml Polybrene (Sigma) to a PA317 subconfluent culture in two cycles of 6 h. In between the two cycles, D-10 medium was replaced overnight with fresh medium. Infected PA317-EGFP- and PA317-PEDF-IRES-EGFP-expressing cells were selected by fluorescence-activated cell sorting on a FAC-Star PLUS flow cytometer (Becton Dickinson, San Jose, CA).

Generation of PEDF-Overexpressing Human Melanoma Cell Lines.
UCD-Mel-N and A375 cell lines were genetically modified by retroviral gene transfer. Briefly, the day before the infection, UCD-Mel-N cells were seeded in a T75 flask (Falcon). A supernatant from the PA317-GFP+ or PA317-PEDF+ confluent flask was recovered at the moment of the infection and filtered through a 45-µm filter. The supernatants were added, together with 8 µg/ml Polybrene (Sigma), to UCD-Mel-N cells in two cycles of 12 h. In between the two cycles, the melanoma cell infection medium was replaced overnight with fresh medium. The transduced melanoma cells [green fluorescent protein (GFP)+, whole, uncloned population] were selected by fluorescence-activated cell sorting (FAC-Star PLUS flow cytometer; Becton Dickinson; Ref. 20 ). PEDF expression was analyzed in conditioned media using anti-PEDF antibodies (a gift from Dr. Noel Bouck).

Tumor and Metastasis Models.
For tumor studies, cells (1.5 x 106 UCD-Mel-N-GFP or UCD-Mel-N-PEDF cells, resuspended in 100 µl of PBS) were injected subcutaneously into the flanks of NOD/SCID mice. Tumors were measured periodically with a caliper, and the volume was calculated as length x width2 x 0.52 (12) . At different time points, the mice were killed, and the tumors were harvested and analyzed.

For metastasis studies, 5 x 105 UCD-Mel-N and A375 cells transduced with retrovirus, resuspended in 100 µl of PBS, were injected intravenously into the tail vein. To evaluate the evolution of the metastases at different organs, the animals were sacrificed, and an autopsy was performed. Critical organs (lung, liver, and brain) were illuminated (490 nm wavelength) to detect fluorescent metastases under a stereomicroscope using a GFP filter. Organs were dissected and fixed in buffered formalin for routine histology and immunohistochemistry.

Detection of Melanoma Cell Arrival at Host Organs.
To assess for melanoma cell homing to specific organs after tail vein injection, PCR amplification of GFP sequences (present in both control and PEDF-transduced cells) was performed using DNA extracted from organs at 16 and 40 h after injection. The presence of a 300-bp band was indicative of GFP-transduced cells.

Metalloproteinase Activity.
Melanoma cells were cultured to near confluence in DMEM-10% FCS. The cell monolayers were washed with PBS and cultured with serum-free DMEM for 24 h. Supernatants were collected and centrifuged to remove floating cells and cell debris. Gelatin zymography was realized according to Heussen and Dowdle (21) . Twenty µl of the supernatants were separated on nonreducing 10% SDS-polyacrylamide gels containing 0.1% (w/v) gelatin (Bio-Rad). After electrophoresis, the gel was washed twice in 50 mM Tris (pH 7.5) containing 2.5% Triton X-100 for 30 min to remove SDS, washed with 50 mM Tris (pH 7.5) twice for 10 min, and then incubated for 24–48 h at room temperature in enzyme substrate buffer [50 mM Tris (pH 7.5), 0.15 M NaCl, 10 mM CaCl2, 0.1% (w/v) Triton X-100, and 0.02% (w/v) NaN3]. Gels were stained with 2.5% Coomassie Blue R-250 for 2–3 h and de-stained with methanol:acetic acid:water (5:1:5).

Migration Assays.
Conditioned media were prepared from 80% confluent melanoma cultures; the cells were rinsed briefly three times with PBS and rinsed with serum-free DMEM for 4 h. Cells were then incubated in fresh serum-free DMEM for 48 h, and the media were collected, centrifuged to remove cell debris, concentrated, and dialyzed using Millipore Ultrafree centrifugal filters with a Mr 10,000 cutoff.

Endothelial or melanoma cell migration was assessed using modified Boyden chamber migration assays as described previously (22) . Briefly, 5 x 105 melanoma cells or human umbilical vascular endothelial cells per cm2 were seeded on gelatin-covered filters, and migration was performed for 4 h for endothelial cells and overnight for melanoma cells. Migration of endothelial cells toward conditioned media from UCD-Mel-N-GFP or UCD-Mel-N-PEDF and migration of melanoma cells toward 10% FCS were tested. Filters were stained using the Diff Quik staining kit, and migrated cells were counted in 10 high-powered fields. Each condition was tested in quadruplicate, and results were confirmed in three independent experiments.

In Vitro Invasion Assay.
Tumor cell invasiveness was tested using gelatin-coated 8-µm pore polycarbonate membranes in transwells inserted in 24-well plates (Costar). Cells (1.65 x 105) were resuspended in 200 µl of DMEM and loaded in the upper compartment. The lower compartment was filled with 600 µl of DMEM and 10% FCS. After 16 h, cell migration was analyzed by detection of enhanced green fluorescent protein (EGFP) using a Leica TCS-SP2 confocal microscope with a x20 oil immersion lens (0.70 NA). Fluorescence images were acquired each 2 µm along the z axis in the transwell and represented by the fluorescence intensity profiles obtained by image analysis using Leica confocal software version 2.5 built 1227. Filter position was determined using reflected light and appears as a white stripe in the projected image. Maximum projections of horizontal (XY) sections corresponding to cells binding to the upper side of the filter, cells that migrated inside the filter, and cells that crossed the filter and bound to the opposite side of the filter were obtained by confocal analysis and quantified using Leica confocal software. Basal migration towards 0.1% bovine serum albumin/DMEM was determined.

In Vivo Angiogenesis Assay.
A corneal neovascularization assay was performed as described previously (23) . Sulcralfate/Hydron pellets were prepared including the indicated substances and implanted into the avascular cornea of anesthetized C57/B16 mice. Where indicated, the pellets contained 0.1 ng/µl basic fibroblast growth factor, 5 ng/ml anti-PEDF antibody (Chemicon), and 30 µg/ml conditioned media from UCD-Mel-N-GFP or UCD-Mel-N-PEDF cells. Results are shown as the number of positive corneas of the total number of corneas implanted. Photos were taken 7 days after implantation.

Vascular Permeability Assay.
Vascular permeability was studied as described by Blazquez et al. (24) . Briefly, tumor-bearing animals were anesthetized, and Evans Blue (1% in PBS; 100 µl/mouse) was injected into the tail vein. Dye leakage was subsequently detected as spots on the tumor surface.

Apoptosis Assays.
For cell cycle analysis by flow cytometry, 80% confluent melanoma cultures were serum-deprived for the indicated time periods in DMEM. For flow cytometry, cells were trypsinized, washed with PBS, and fixed in 70% ethanol pre-cooled at 4°C. Fixed cells were washed with PBS before treatment with 100 µg/ml RNase A and staining with 50 µg/ml propidium iodide for 30 min at 37°C. Results of a representative experiment, confirmed in three independent experiments, are shown.

Anoikis assays were performed in poly-HEMA-coated tissue culture dishes to prevent cell adhesion to the plate. Dishes were coated with a 10 mg/ml poly-HEMA solution in 95% ethanol and washed extensively with PBS before use. Cells were seeded at a density of 4 x 105 to 8 x 105 cells/ml in DMEM/10% FCS. Cells were harvested at the indicated time points and processed for flow cytometry as indicated above.

To detect apoptosis [terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL)-positive cells] in the subcutaneous tumors, formaldehyde-fixed sections were processed using an in situ cell death detection kit (Roche, Indianapolis, IN) per the manufacturer’s instructions. Negative control slides were incubated in reaction mixture without terminal deoxynucleotidyl transferase.

Cell Proliferation and Viability Assays.
Proliferation of UCD-Mel-N-GFP and UCD-Mel-N-PEDF cells was assessed using a 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt or MTT assay to determine the number of viable cells (Roche). Cells (103) were seeded in 96-well plates in DMEM containing 10% FCS and processed at the indicated days of culture following the manufacturer’s instructions. Each condition was tested in quadruplicate, and results were confirmed in three independent experiments.

Angiogenic Factor Expression.
Vascular endothelial growth factor (VEGF) was quantified in conditioned media from UCD-Mel-N-GFP and UCD-Mel-N-PEDF cells by enzyme-linked immunosorbent assay (R&D). Cells were grown in 24-well dishes to near confluence, and medium was conditioned for 24 h. VEGF determinations were performed in triplicate, and results were confirmed in two independent experiments.

Angiopoietin 1 and 2 levels in UCD-Mel-N-GFP and UCD-Mel-N-PEDF cells were determined by Northern blot analysis using poly(A)+ RNA. Northern blots were performed on nylon membranes (Biodyne; Pall Corp.) following standard protocols (25) . Angiopoietin probes (a 500-bp fragment of human angiopoietin 1 and 2 cDNAs was generously provided by Dr. H. Augustin) were labeled by a random priming method (Ready-To-Go DNA labeling beads; Amersham). Hybridizations were carried out overnight at 65°C in 7% SDS, 500 mM sodium phosphate (pH 7.2), and 1 mM EDTA (26) . Filters were washed twice in 1% SDS and 40 mM sodium phosphate (pH 7.2) at 65°C. A RNA ladder (Invitrogen) was used to estimate messenger RNA size. Membranes were exposed to X-ray films (Konica Minolta). Quantifications were carried out by detecting radioactive signals in the filters using an Instantimager counter (Packard). Cyclophilin was used as a loading control. Results were confirmed in two independent experiments.

Histology, Immunohistochemistry, and Immunofluorescence.
Tumors and lung metastases were analyzed by histological and immunohistochemical techniques. Tissues were formalin-fixed, embedded in paraffin, sectioned, and subjected to H&E or immunohistochemical staining.

To determine vessel maturation in subcutaneous tumors and in lung metastases, formaldehyde-fixed sections were immunostained with antibodies specific for smooth muscle actin [SMA (anti-SMA)] or S100, respectively. The anti-SMA primary antibody (Sigma) was diluted 1:400, and the S100 primary antibody was diluted 1:100. Tumor vascular density was determined in snap-frozen tissue sections fixed with cold acetone. Slides were incubated with antimouse CD31 (PharMingen) diluted 1:100. For immunoperoxidase staining, primary antibodies were incubated for 1 h at 37°C. The secondary biotinylated antisera selected according to the origin of the first antibody (all of the antibodies were supplied by Jackson ImmunoResearch) were incubated at the final dilution recommended by the manufacturer for 45 min at room temperature, followed by the avidin-biotin complex method (Elite kit; Vector). The peroxidase activity was then visualized with diaminobenzidine and H2O2 (Vector), followed by counterstaining with hematoxylin. A total of 10 nonoverlapping fields at x40 magnification from two tumors were counted for CD31 quantitative analysis. Data are expressed as the mean number of CD31-positive vessels per field. For double immunofluorescence detection of CD31 and SMA, 10-µm frozen sections were fixed in 1:1 methanol-acetone and incubated with combined primary antibodies. Fluorescent secondary antibodies against mouse (Texas Red-conjugated) and rat (FITC-conjugated) inmunoglobulins were used. A total of 100 vessels in nonoverlapping fields were scored for quantitative analysis of CD31/SMA labeling.

To determine the tumor proliferative index, mice received intraperitoneal injection with 100 mg/kg 5-bromo-2'-deoxyuridine (BrdUrd) in 0.9% NaCl and were sacrificed 1 h later for tissue harvesting. To detect BrdUrd incorporation, deparaffinized tumor sections were incubated in 2N HCl for 1 h at room temperature. After washing in PBS, the sections were incubated with mouse anti-BrdUrd antibody for 1 h at room temperature. Anti-BrdUrd (Roche) primary antibody was diluted 1:50.

Different methods were used to determine the EGFP reporter gene expression. Green fluorescence was readily visualized in the intact xenograft in vivo with a fluorescence stereomicroscope (Olympus) under blue light. Formaldehyde-fixed sections were subjected to immunohistochemistry (see above) with anti-GFP polyclonal antibodies (A-11122; Molecular Probes) at a 1:200 dilution.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
PEDF-Transduced Melanoma Cells Secrete Biologically Active PEDF.
To determine the possible effects of PEDF on melanoma growth, we generated populations overexpressing human PEDF through retroviral gene transfer. The bicistronic retroviral construct included human PEDF cDNA followed by an internal ribosomal entry site (IRES) coupled to EGFP cDNA (Fig. 1A)Citation . UCD-Mel-N [a human melanoma cell line derived from a patient with multiple primary melanoma tumors (27) ] melanoma cells were transduced and sorted for EGFP expression. Control cells were transduced with the same retroviral construct lacking the PEDF cDNA. Conditioned media from both control and PEDF-transduced cells were tested for PEDF expression by Western blot. The presence of a robust, specific Mr 55,000 band in the PEDF-transduced cells (UCD-Mel-N-PEDF) indicated that PEDF was appropriately synthesized and processed (Fig. 1B)Citation . The biological activity of PEDF secreted by transduced melanoma cells was determined by an endothelial cell migration assay (22) . Consistent with the effects reported for recombinant PEDF (28) , conditioned medium from UCD-Mel-N-PEDF cells failed to stimulate endothelial cell chemotaxis above basal levels (Fig. 1C)Citation , whereas conditioned medium from UCD-Mel-N-GFP control melanoma cells induced migration at high levels. This result was confirmed in vivo in a corneal neovascularization assay. Media from UCD-Mel-N-GFP cells were highly angiogenic, whereas media conditioned by PEDF-positive cells were no longer stimulatory. The lack of angiogenic response to conditioned media from PEDF-transduced cells was due to PEDF because angiogenic activity was restored by adding the blocking anti-PEDF antibodies. These results indicate that PEDF is able to counterbalance the angiogenic stimulus produced by melanoma cells (Fig. 1D)Citation .



View larger version (55K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Expression and biological activity of PEDF produced by transduced human melanoma cells. A, PEDF bicistronic retroviral construct. B, PEDF expression detected by Western blot in the conditioned media from UCD-Mel-N cells transduced with GFP (control) or PEDF retroviruses. C, activity of conditioned media produced by PEDF-transduced or control melanomas using an endothelial cell migration assay. Standard errors are shown, and asterisks indicate significant differences. ***, P < 0.001 as compared with migration of endothelial cells toward conditioned media from UCD-Mel-N-GFP. D, in vivo corneal angiogenesis assay to evaluate the angiogenic activity of conditioned media from UCD-Mel-N-GFP and UCD-Mel-N-PEDF cells. Anti-PEDF antibodies were used to demonstrate that PEDF is responsible for the antiangiogenic activity of UCD-Mel-N-PEDF conditioned medium. Photographs were taken 7 days after implantation. Quantitative data of corneal micropocket assay are shown as number of positive corneas/total corneas implanted. Asterisk indicates inflammatory response.

 
PEDF Impaired Subcutaneous Melanoma Growth.
To rule out possible toxic effects of PEDF on melanoma cells, we compared the proliferation rates of GFP control and PEDF-transduced cells in vitro. Typically, under standard culture conditions (10% serum), PEDF-positive cells remained attached to the plastic substrate and proliferated at rates similar to those of control cells (Fig. 2A)Citation .



View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Effect of PEDF overexpression on xenografted subcutaneous human melanomas. A, proliferation curves of PEDF-transduced or control melanoma cells growing in the presence of serum. B, tumor volume of PEDF and control melanomas at 30 and 90 days after cell injection. Results (mean ± SE) are from six mice in each group. **, P < 0.01.

 
We subsequently evaluated the growth of subcutaneous tumors formed by the retrovirally modified melanoma cell lines in immunodeficient NOD/SCID mice at different time points. Initially, both control and PEDF melanoma tumors grew at a similar rate and reached similar volumes in the first 4 weeks. However, the growth of PEDF-positive melanomas became highly inhibited thereafter (Fig. 2B)Citation . Histological examination at 12 weeks revealed extensive necrotic areas in the PEDF-positive tumors, but not in control tumors (Fig. 3A)Citation . To determine whether a growth impediment at later stages resulted from angiogenic switch inhibition by PEDF, we assessed both functional and quantitative markers of tumor vasculature at earlier time points, when size differences between control and PEDF tumors were not yet statistically significant. Thus, tumors were harvested at 18 and 30 days after injection. At 30 days, the Evans Blue permeability assay revealed severely reduced vascular leakage (Fig. 3B)Citation , whereas CD31 staining demonstrated a dramatic decrease in neovascularization in the UCD-Mel-N-PEDF compared with control GFP tumors (Fig. 3C)Citation . Vascular density differences were also apparent (although not statistically significant) at 18 days (Fig. 3C)Citation .



View larger version (69K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Histopathology and angiogenic performance of PEDF-transduced subcutaneous melanomas. A, extended necrosis in PEDF-transduced melanomas (H&E staining, right panels) compared with control melanomas. Arrowheads indicate blood lakes in the control melanomas (H&E staining, left panels). A blood vessel remnant in the PEDF tumor is indicated by an arrow (bottom right panel). B, Evans Blue permeability assay in control (left panel) and PEDF tumor (right panel). C, microvessel density (CD31) of PEDF and control melanomas at 18 days and 30 days. Bar graphs at the bottom show quantification of CD31-positive cells. Standard errors are shown, and asterisks indicate significant differences. ***, P < 0.001. D, immunoperoxidase detection of SMA in control (left panels) and PEDF tumors (right panels). Low magnification (x10), middle panels. High magnification (x40), bottom panels. E, detection of SMA in tumor microvessels by double immunofluorescence. Microvessels (CD31) are visualized in green (FITC label), and SMA coverage is visualized in red (Texas Red label). Bar graph shows the percentage of SMA-positive vessel staining.

 
Also consistent with angiogenic switch reversal, SMA, a marker of periendothelial cells indicative of vascular maturity, was observed in the vessels found at 12 weeks in residual UCD-Mel-N-PEDF tumors (likely the preexisting capillaries that favor initial tumor growth). In contrast, control UCD-Mel-N-GFP tumors showed highly dilated vessels not decorated by SMA-positive cells, consistent with immature, remodeling vessels (Fig. 3D)Citation . This feature was also evident in early tumors. In fact, the majority of vessels in the control tumors (GFP tumors) showed a SMA-negative/CD31-positive phenotype at both 18 and 30 days after injection. Conversely, tumors generated from PEDF-transduced cells exhibited a greater proportion of SMA-positive/CD31-positive vessels (Fig. 3, D and E)Citation .

We also determined the effect of PEDF on proliferation and apoptosis in the subcutaneous tumors. UCD-Mel-N-PEDF tumors showed highly reduced BrdUrd incorporation compared with GFP-only controls 30 days after injection (Fig. 4A)Citation . As in the case of vascular density, differences in cell proliferation were not statistically significant at 18 days (Fig. 4A)Citation . These results indicate that tumor growth collapse, likely due to impaired vascularization, occurs around 20–30 days after injection. In fact, massive tumor cell apoptosis is present at 30 days but only slightly increased at 18 days in the PEDF tumors (Fig. 4B)Citation . The increase in TUNEL-positive cells in tumors at 30 days ranged from moderate to high, depending on the tumor areas inspected, whereas control tumors presented few homogeneously distributed apoptotic cells (Fig. 4B)Citation . A progressive increase in overall apoptosis and necrosis was found throughout tumor development in PEDF-positive melanomas (data not shown).



View larger version (60K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Effect of PEDF overexpression on proliferation and apoptosis of subcutaneous UCD-Mel-N human melanomas. A, proliferation assessed by BrdUrd incorporation in control and PEDF melanomas at 18 and 30 days. BrdUrd-positive cells were counted in five fields in sections from control ({square}) or PEDF tumors ({cjs2108}). **, P < 0.01; ***, P < 0.001 for PEDF tumor as compared with control tumor. B, apoptosis assessed by TUNEL. TUNEL-positive cells were counted in five fields in sections from control ({square}) or PEDF tumors ({cjs2108}). **, P < 0.01; ***, P < 0.001 for PEDF tumor as compared with control tumor.

 
PEDF Abrogated Melanoma Metastasis Potential in the Tail Vein Model.
Tumor dissemination in critical organs such as the lung, brain, and liver is the main cause of death in melanoma patients. Strong suppression of the growth of subcutaneous (primary) melanoma by PEDF compelled us to study its effect on the growth and spread of melanoma metastases. To that end, UCD-Mel-N-GFP control and UCD-Mel-N-PEDF cells were injected intravenously in immunodeficient NOD/SCID mice, and metastases were analyzed macroscopically in different organs by GFP fluorescence. Remarkably, 3 months after injection, 100% of the animals injected with UCD-Mel-N-GFP cells (n = 6; two experiments) developed large, visible lung nodules, which were visible under both white and blue light (GFP fluorescence), whereas none of the animals that received UCD-Mel-N-PEDF cells showed visible signs of metastases (Fig. 5, A and C)Citation . Histological examination and immunostaining for S100, a melanoma marker of serial sections of lungs, failed to reveal the presence of micrometastases in UCD-Mel-N-PEDF-injected mice even at the longest times analyzed, whereas UCD-Mel-N-GFP-injected mice all had metastases (Fig. 5, B and C)Citation . This fact led us to speculate whether melanoma cell homing to the target organ could be compromised. However, this was not the case because PCR analysis detected GFP DNA sequences in two of three and three of four lungs of UCD-Mel-N-GFP- and UCD-Mel-N-PEDF-injected mice, respectively. (Fig. 5D)Citation .



View larger version (82K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Effect of PEDF overexpression on the metastatic potential of UCD-Mel-N human melanomas. A, macroscopic appearance and GFP fluorescence of lung metastatic nodules 90 days after tail vein injection of UCD-Mel-N-GFP cells (top panels) and unaffected lungs after injection of UCD-Mel-N-PEDF cells (bottom panels). B, H&E staining of macrometastases corresponding to UCD-Mel-N-GFP-injected mouse lungs (top panel). Inset shows S100 staining of a consecutive section. Bottom panel shows H&E staining of an unaffected lung from a mouse that received injection with UCD-Mel-N-PEDF melanoma cells. Quantitative data of melanoma metastasis incidence in a representative experiment at 30 and 90 days are also shown (bar graph). C, H&E staining, GFP immunostaining, and GFP fluorescence at different time points. Note the absence of micrometastasis in UCD-Mel-N-PEDF-injected mice lungs (right panels). D, PCR analysis of GFP cDNA in lungs from mice that received injection with UCD-Mel-N-PEDF or control cells. The lane indicated by an asterisk corresponds to amplification of DNA extracted from GFP-positive cells.

 
PEDF Inhibits Melanoma Cell Migration and Survival.
The complete prevention of metastasis formation suggested that, in addition to the canonical inhibition of angiogenesis, PEDF also exerted a direct effect on melanoma cells that may contribute to the blockade of metastases. One attractive possibility was that PEDF could influence the migration of the melanoma cells into the new host "soil." Therefore, we assessed the effect of PEDF gene transduction on melanoma cell migration. PEDF-positive melanoma cells showed significantly lower chemotaxis in modified Boyden chamber assay (Fig. 6A)Citation . Invasive properties of PEDF-secreting melanoma cells were compared with control melanoma cells using a transwell assay. We found a significant reduction in the number of cells that penetrated the filter and traversed the pores in PEDF-positive cells compared with GFP control (Fig. 6, B and C)Citation . Quantitative data analysis showed a 3- to 5-fold reduction in migration and invasiveness of UCD-Mel-N-PEDF cells.



View larger version (49K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Inhibition of melanoma cell migration and invasiveness by PEDF. A, migration of PEDF-transduced melanoma cells compared with control melanoma cells in Boyden chamber chemotaxis assay. Cells that migrated toward 10% FCS were evaluated in 10 high-power fields. {square}, UCD-Mel-N-GFP cells; {cjs2108}, PEDF cells. Standard errors are shown, and asterisks indicate significant differences. ***, P < 0.001 as compared with control UCD-Mel-N-GFP melanoma cells. B, transwell invasiveness assay of PEDF-transduced melanoma cells. Fluorescence images were acquired each 2 µm along the z axis in the transwell and are represented by fluorescence intensity profiles obtained by image analysis using Leica confocal software. The position of the filter is localized using reflected light and appears as a white stripe in the projected image. Position of the filter was localized using reflected light and is indicated in the fluorescence intensity profiles. C, maximum projections of horizontal sections corresponding to cells binding to the upper side of the filter (left panels), cells that migrated inside the filter (middle panels), and cells that crossed the filter and bound to the opposite side (right panels) are also shown.

 
Seeking mechanisms underlying impaired migration, we investigated matrix metalloproteinase profiles of PEDF-positive and GFP control cells. We were able to detect a high matrix metalloproteinase-2 activity by gelatin zymogrphy in conditioned media from melanoma cells; however, no clear differences have been found between PEDF-transduced and control cells (data not shown).

We next investigated whether attenuated migration of PEDF-transduced melanoma cells may result from a PEDF-dependent decrease in cell survival. We therefore tested apoptosis of PEDF-positive cells and control cells under different environmental challenges (Figs. 7Citation and 8)Citation . Although under standard culture conditions (full serum), both control and PEDF-transduced melanoma cells grew at similar rates (Fig. 2A)Citation , serum withdrawal resulted in a higher number of detached cells in the PEDF-transduced cultures (data not shown).



View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 7. Induction of apoptosis by PEDF in melanoma cells. A, viability assay of PEDF-transduced melanoma compared with control melanoma in the absence of serum. Standard errors are shown, and asterisks indicate significant differences. **, P < 0.01 as compared with viability of control UCD-Mel-N-GFP melanoma cells. B, induction of apoptosis by PEDF on apoptosis as evaluated by flow cytometric determination of DNA content in UCD-Mel-N-GFP or UCD-Mel-N-PEDF cells at 16, 24, and 48 h after serum repletion. Individual nuclear DNA content as reflected by fluorescence intensity of incorporated propidium iodide is plotted as a histogram. Histograms are derived from a representative experiment. Quantification of apoptotic cells (sub-G0 population) is also shown (bar graph).

 


View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 8. Induction of anoikis by PEDF in melanoma cells. A, induction of anoikis by PEDF as evaluated by flow cytometric determination of DNA content in UCD-Mel-N-GFP or UCD-Mel-N-PEDF cells after 48 and 72 h of suspension culture. Individual nuclear DNA content as reflected by fluorescence intensity of incorporated propidium iodide is plotted as a histogram. Histograms are derived from a representative experiment. Quantification of apoptotic cells (sub-G0 population) is also shown (bar graph).

 
A viability assay showed that UCD-Mel-N-PEDF cells progressively lost viability in the absence of serum (Fig. 7A)Citation . Consistently, quantitative measurement of apoptosis using flow cytometry analysis of DNA content revealed a significant increase in programmed cell death in the absence of mitogenic stimuli in the PEDF-positive population (Fig. 7B)Citation . The percentage of apoptotic cells increased in a time-dependent manner in the absence of serum in UCD-Mel-N-PEDF cells, whereas it remained at a constant low level in control UCD-Mel-N-GFP cells.

We also tested whether the lack of attachment could differentially induce apoptosis in PEDF-transduced melanoma cells. This type of cell stress, known as anoikis, could be significant in a context in which metastasizing cells have to survive en route to the target organ (29) . After 48–72 h of suspension culture in high serum, a high proportion of PEDF-transduced cells showed a DNA content consistent with apoptotic cell death due to loss of cell anchorage (Fig. 8)Citation . The kinetics of anoikis was further accelerated when PEDF-positive cells were grown in suspension in the absence of serum (data not shown).

Angiogenic Factor Profile of PEDF-Transduced Melanoma Cells.
PEDF has been shown to exert antiangiogenic activity by antagonizing VEGF action at the level of endothelial cell responses, and the VEGF/PEDF ratio is altered in ischemia-induced neovascular growth (30) . However, little is known about possible modulation of angiogenic/antiangiogenic factor expression by PEDF. We thus studied the expression of VEGF (a relevant proangiogenic factor) and angiopoietins 1 and 2 (two important regulators whose balance controls the onset of the angiogenic process).

Surprisingly, enzyme-linked immunosorbent assay for human VEGF revealed that the expression of VEGF protein secreted in the conditioned medium of UCD-Mel-GFP (control) cells was 5-fold higher than that of PEDF-transduced cells (313 versus 74 pg/106 cells/24 h, respectively; Fig. 9ACitation ). Northern blot analysis of angiopoietin expression revealed a 2.6-fold increase in angiopoitein-2 messenger RNA levels in the PEDF-transduced cells (Fig. 9B)Citation , whereas angiopoietin-1 levels remained unchanged. This result was further confirmed by Western blot analysis of melanoma cell conditioned media (data not shown).



View larger version (39K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 9. VEGF and angiopoietin levels in UCD-Mel-N human melanoma cells transduced by PEDF. A, VEGF levels in conditioned media from control and PEDF melanoma cells determined by enzyme-linked immunosorbent assay. The data presented were obtained from two independent experiments and are expressed as pg of VEGF/106 cells/24 h (mean ± SD; n = 2). B, Northern blot of angiopoietin 1 and 2 expression in control and PEDF melanomas. Quantification is shown in the bar graphs.

 
PEDF Blocks Melanoma Metastasis to a Broad Spectrum of Targets.
We finally investigated whether inhibition of metastatic growth by PEDF was restricted to a particular melanoma cell type/host microenvironment or whether, on the contrary, it exhibited a broader inhibitory activity. We studied the effect of PEDF on the metastatic growth of the A375 melanoma cell clone with liver tropism in NOD/SCID mice using the same tail vein injection protocol. A375 melanoma cells transduced with PEDF retroviral vector also secreted high levels of PEDF in conditioned medium (Fig. 10A)Citation . Remarkably, as was the case for UCD-Mel-N-PEDF cells in the lung, metastases were abolished in the livers of five of six mice that received injection with PEDF-transduced A375 cells (Fig. 10B)Citation . Moreover, the single micrometastasis found in the liver of the only metastasis-positive mouse that received injection with PEDF-transduced melanoma cells stained negative for GFP. This may indicate either silencing of the transgene or contamination with nontransduced cells, which accounts for the appearance of the metastasis in this mouse. In contrast, histological examination of liver sections from animals that received injection with control cells 3 months after tail vein injection revealed a high infiltration of melanoma cells (both macrometastases and micrometastases; Fig. 10BCitation ) throughout the hepatic parenchyma.



View larger version (35K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 10. Inhibition of the metastatic potential of A375 human melanomas by PEDF transduction. A, PEDF expression detected by Western blot in conditioned media from A375 cells transduced using control or PEDF retrovirus. B, H&E staining of liver sections from a representative mouse that received injection with either A375-GFP cells (left panel) or A375-PEDF cells (right panel). Quantitative data of A375-GFP and A375-PEDF melanomas metastasis incidence in liver 90 days after injection are shown as either macroscopic metastasis/total mice or microscopic metastasis/total mice.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Combating melanoma metastasis remains a major clinical challenge, and thus far, the existing therapeutic protocols have proven disappointing. Novel approaches include the use of promising angiogenesis inhibitors. The armory of such agents includes PEDF, a pleiotropic factor initially identified as a neurotrophin (8) . In this study, we show that PEDF potently inhibits primary melanoma growth and completely prevents the development of metastases.

According to evidence accumulated mostly from studies of vascular pathologies in the eye, PEDF antagonizes the proangiogenic effect of VEGF. Moreover, attenuation of constitutive PEDF antiangiogenic activity promotes the activation and remodeling of previously quiescent vasculature (30) . In our system, the reduction of both vascular leakage and vessel counts early in the progression of PEDF-positive melanomas, as well as the existence of a majority of SMA-positive blood vessels in the tumors overexpressing PEDF, suggests that PEDF precludes the development of immature vessels capable of rapid remodeling. The persistence of pericytes in PEDF tumors may be indicative of preexisting mature vessels resistant to destabilization by PEDF. The strong reduction in VEGF levels concomitant with an increase in angiopoietin 2 expression observed in PEDF-transduced melanoma cells reverses the angiogenic balance determining an inhibition of tumor angiogenesis. Increased levels of angiopoietin 2 in the absence of VEGF trigger endothelial cell apoptosis and vessel regression (31 , 32) . PEDF has recently been shown to block angiogenesis through antioxidative pathways that negatively regulate VEGF (32 , 33) . While this manuscript was under revision, Guan et al. (34) reported similar results showing that PEDF overexpression in a glioma cell line induced changes in the angiogenic factor profile, including down-regulation of VEGF expression.

Signal transduction pathways mediating PEDF antiangiogenic actions remain almost unexplored. It has been reported that PEDF binds immobilized heparin, chondroitin sulfate, dextran sulfate, cell surface glycosaminoglycans (GAG), and collagen (35, 36, 37) . PEDF binds specifically to the Y-79 retinoblastoma and cerebral granule cells, and its neurotrophic effects are presumably associated with a Mr 80,000 surface protein (38 , 39) . The GAG binding region was identified by homology modeling with the structures of antithrombin III and ovalbumin. Two peptides from the center of ß-sheet, A-strands 2 and 3, and helix F with a basic surface potential, densely populated with the exposed lysines, are available to interact with GAG and polyanions (35) . Binding to the positively charged external collagen areas requires a negatively charged surface region rich in acidic residues. This PEDF domain has no neurotrophic effect and may convey antiangiogenic acitivty (37) . PEDF neurotrophic function and the ability to block vascular leakage are replicated by a 44-amino acid peptide (44-mer, residues 58–101; Refs. 36 and 40 ). Interestingly, four amino acids within 44-mer (Glu101, Ile103, Leu112, and Ser115) are critical for the effect on vascular permeability (40) , and the same residues may be responsible for PEDF angioinhibitory properties.

Whereas the robust effect of PEDF on primary melanoma development could be explained solely by its bona fide potent antiangiogenic action (28) , the ability of PEDF to induce apoptosis directly in melanoma cells, described herein, likely produces a synergistic effect when antisurvival challenges (such as hypoxia) are present and presumably contributes to the antitumor and antimetastatic activities of PEDF. Our data are consistent with the recently shown ability of PEDF to induce apoptosis in cultured prostate epithelium and to reduce angiogenesis in prostate tumor xenografts after intratumor injections (13) . Also in accordance with our results, gene therapy approaches using adenoviral PEDF gene transfer to different cell lines, including those derived from lung, colon, and liver tumors, have proven efficient to inhibit xenografted tumor growth (12 , 41) . Additional experimental evidence for PEDF as a widespread antitumor agent has been provided during the revision of this manuscript. These reports include two studies using PEDF overexpression in melanoma primary xenografts (42) and glioma cells (34) and a clinical study correlating PEDF expression and prognosis of patients with pancreatic adenocarcinoma metastasis to the liver (43) .

During the metastatic process, as tumor cells detached from the primary tumor migrate through the surrounding tissue, enter the circulation, invade, and reattach, each such step represents a different type of selective pressure, which, for the majority of cells, results in failure to survive. Thus, each step in the metastatic cascade is potentially rate-limiting, and the failure to complete a single step is likely to render a tumor cell nonmetastatic. The tail vein injection model allows assessment of rate-limiting events (namely, the ability to survive in the bloodstream, to adhere to the vascular endothelium of capillary walls, to extravasate, and to grow in a different tissue at a distant site) at a late stage of the metastatic process. Because we were able to detect PEDF-transduced melanoma cells at the target organ, it appears that short-term cell survival in the circulation and adhesion to the endothelium were not compromised by PEDF. However, the stress suffered by loosely attached melanoma cells favored programmed cell death by anoikis in the presence of PEDF. Increased cell death at this step would hinder further events such as migration, extravasation, and growth at a remote secondary site. However, it is not evident that increased anoikis is the only reason for diminished migratory and invasive capacity by PEDF-producing cells. Inability to migrate alone could serve as a limiting factor for metastasis formation. The complete lack of metastatic foci in the lungs of mice that received injection with PEDF-transduced melanoma cells precluded analysis of tumor cell apoptosis as a possible mechanism underlying the antimetastatic effect of PEDF.

The induction of apoptosis by PEDF in tumor cells (the nonendothelial compartment of the tumor) may represent a broader class of events, provided that appropriate challenge takes place. In fact, PEDF enhancement of apoptosis due to hypoxia or mimicking conditions in prostate tumor cells has been demonstrated (13) . It is possible that under stress conditions, PEDF induces apoptotic cascades in melanoma cells similar to apoptotic cascades induced in endothelial cells (23) . It appears even more feasible because some highly invasive melanoma types are capable of the vascular mimicry phenomenon (44) . PEDF could be exploiting this trait by inhibiting melanoma cell invasion or incorporation into tumor vessels among endothelial cells, thus decreasing the frequency of metastasis and diminishing the number of mosaic vessels. The direct effects of PEDF on melanoma cells described in this study broaden the plethora of targets and processes affected by this factor (8) . The fact that neural crest progenitors give rise to both neural cells and melanocytes and that particular cranial neural crest cells can generate the endothelium of the aortic arteries suggests that seemingly contradictory effects of PEDF may converge at the level of the ancestral origin of the cells affected. For example, migration, one of the common features for neural crest progenitors and their derivatives, is most dramatically affected by PEDF. Notwithstanding the complexity of response to PEDF treatment and/or expression, the dual antitumor and antiangiogenic activity doubles the efficacy and promise of PEDF as an agent for the treatment of malignant melanoma. Studies are in progress to assess the efficacy of systemic PEDF application to combat melanoma metastases.


   ACKNOWLEDGMENTS
 
We are indebted to Isabel de los Santos and Pilar Hernandez for histology, Jesus Martinez for animal care, Drs. C. Gamallo and A. Bravo for expert advice on pathology, Yajaira Suarez for advice in flow cytometry, and D. Megias for confocal analysis of migration assays.


   FOOTNOTES
 
Grant support: Grants SAF-2001-1349 (B. Jimenez) and BMC-2001-1018 from Ministerio de Ciencia y Tecnología (J. Jorcano), Grant FIS 01/0556 from Ministerio de Sanidad y Consumo (F. Larcher), and Grant CAM 08.6/0004 (M. Del Rio). M. Garcia and N. Fernandez were supported by Comunidad Autonoma de Madrid fellowships.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: B. Jimenez, F. Larcher, and M. Del Rio contributed equally to this work.

Requests for reprints: Benilde Jimenez, Department of Biochemistry, Universidad Autónoma de Madrid-Instituto de Investigaciones Biomédicas CSIC-UAM, Arturo Duperier 4, 28029 Madrid, Spain. E-mail: bjimenez{at}iib.uam.es; Fax: 34-91-5854401; Phone: 34-91-5854484; or Marcela Del Rio, Project on Damage, Repair and Tissue Engineering, CIEMAT, Avenida Complutense 22, 28040 Madrid, Spain. E-mail: marcela.delrio{at}ciemat.es; Fax: 34-91-3466484; Phone: 34-91-3466051.

Received 1/23/04. Revised 6/ 3/04. Accepted 6/23/04.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Tucker MA, Goldstein AM. Melanoma etiology: where are we?. Oncogene, 22: 3042-52, 2003.[CrossRef][Medline]
  2. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer, 3: 559-70, 2003.[CrossRef][Medline]
  3. Dredge K, Dalgleish AG, Marriott JB. Angiogenesis inhibitors in cancer therapy. Curr Opin Investig Drugs, 4: 667-74, 2003.[Medline]
  4. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene, 22: 3138-51, 2003.[CrossRef][Medline]
  5. Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene, 22: 3172-9, 2003.[CrossRef][Medline]
  6. Li G, Satyamoorthy K, Meier F, et al Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene, 22: 3162-71, 2003.[CrossRef][Medline]
  7. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 3: 401-10, 2003.[CrossRef][Medline]
  8. Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci, 4: 628-36, 2003.[CrossRef][Medline]
  9. Stellmach V, Crawford SE, Zhou W, Bouck N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA, 98: 2593-7, 2001.[Abstract/Free Full Text]
  10. Crawford SE, Stellmach V, Ranalli M, et al Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci, 114: 4421-8, 2001.
  11. Abramson LP, Stellmach V, Doll JA, et al Wilms’ tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model. J Pediatr Surg, 38: 336-42, 2003.[CrossRef][Medline]
  12. Wang L, Schmitz V, Perez-Mediavilla A, et al Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther, 8: 72-9, 2003.[CrossRef][Medline]
  13. Doll JA, Stellmach VM, Bouck NP, et al Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med, 9: 774-80, 2003.[CrossRef][Medline]
  14. Jaffe E, Nachman RL, Becker CG, Minick RC. Culture of human endothelial cells derived from umbilical veins. Circulation, 46: 211-53, 1972.
  15. Reed JA, Bales E, Xu W, et al Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling. Cancer Res, 61: 8074-8, 2001.[Abstract/Free Full Text]
  16. Chen D, Xu W, Bales E, et al SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res, 63: 6626-34, 2003.[Abstract/Free Full Text]
  17. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther, 7: 1405-13, 1996.[Medline]
  18. Yang S, Delgado R, King S, et al Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther, 10: 123-32, 1999.[CrossRef][Medline]
  19. Larcher F, Del Rio M, Serrano F, et al A cutaneous gene therapy approach to human leptin deficiencies: correction of the murine ob/ob phenotype using leptin-targeted keratinocytes grafts. FASEB J, 15: 1529-38, 2001.[Abstract/Free Full Text]
  20. Del Rio M, Larcher F, Serrano F, et al A preclinical model for the analysis of genetically modified human skin in vivo. Hum Gene Ther, 20: 959-68, 2002.[CrossRef]
  21. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem, 102: 196-202, 1980.[CrossRef][Medline]
  22. Polverini PJ, Bouck NP, Rastinejad F. Assay and purification of a naturally occurring inhibitor of angiogenesis. Methods Enzymol, 198: 440-50, 1991.[Medline]
  23. Volpert OV, Zaichuk T, Zhou W, et al Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med, 8: 349-57, 2002.[CrossRef][Medline]
  24. Blazquez C, Casanova ML, Planas A, et al Inhibition of tumor angiogenesis by cannabinoids. FASEB J, 17: 529-31, 2003.[Abstract/Free Full Text]
  25. Sambrook J, Fritsch EF, Maniatis T. . Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press Cold Spring Harbor, NY 1989.
  26. Church GM, Gilbert W. Genome sequencing. Proc Natl Acad Sci USA, 81: 1991-5, 1984.[Abstract/Free Full Text]
  27. Xu W, Angelis K, Danielpour D, et al Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor. Proc Natl Acad Sci USA, 97: 5924-9, 2000.[Abstract/Free Full Text]
  28. Dawson DW, Volpert OV, Gillis P, et al Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science (Wash DC), 285: 245-8, 1999.[Abstract/Free Full Text]
  29. Zhu Z, Sanchez-Sweatman O, Huang X, et al Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res, 61: 1707-16, 2001.[Abstract/Free Full Text]
  30. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med, 8: 330-4, 2002.[CrossRef][Medline]
  31. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA, 97: 11205-10, 2002.
  32. Yamagishi S, Amano S, Inagaki Y, et al Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. Microvasc Res, 65: 186-90, 2003.[CrossRef][Medline]
  33. Yamagishi S, Inagaki Y, Amano S, et al Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun, 296: 877-82, 2002.[CrossRef][Medline]
  34. Guan M, Pang CP, Yam HF, et al Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor. Cancer Gene Ther, 11: 325-32, 2004.[CrossRef][Medline]
  35. Alberdi E, Hyde CC, Becerra SP. Pigment epithelium-derived factor (PEDF) binds to glycosaminoglycans: analysis of the binding site. Biochemistry, 37: 10643-52, 1998.[CrossRef][Medline]
  36. Bilak MM, Becerra SP, Vincent AM, et al Identification of the neuroprotective molecular region of pigment epithelium-derived factor and its binding sites on motor neurons. J Neurosci, 22: 9378-86, 2002.[Abstract/Free Full Text]
  37. Meyer C, Notari L, Becerra SP. Mapping the type I collagen-binding site on pigment epithelium-derived factor. Implications for its antiangiogenic activity. J Biol Chem, 277: 45400-7, 2002.[Abstract/Free Full Text]
  38. Alberdi E, Aymerich MS, Becerra SP. Binding of pigment epithelium-derived factor (PEDF) to retinoblastoma cells and cerebellar granule neurons. Evidence for a PEDF receptor. J Biol Chem, 274: 31605-12, 1999.[Abstract/Free Full Text]
  39. Aymerich MS, Alberdi EM, Martinez A, Becerra SP. Evidence for pigment epithelium-derived factor receptors in the neural retina. Investig Ophthalmol Vis Sci, 42: 3287-93, 2001.[Abstract/Free Full Text]
  40. Liu H, Ren JG, Cooper WL, et al Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA, 101: 6605-10, 2004.[Abstract/Free Full Text]
  41. Mahtabifard A, Merritt RE, Yamada RE, Crystal RG, Korst RJ. In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies. J Thorac Cardiovasc Surg, 126: 28-38, 2003.[Abstract/Free Full Text]
  42. Abe R, Shimizu T, Yamagishi S, et al Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol, 164: 1225-32, 2004.[Abstract/Free Full Text]
  43. Uehara H, Miyamoto M, Kato K, et al Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res, 64: 3533-7, 2004.[Abstract/Free Full Text]
  44. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Molecular plasticity of human melanoma cells. Oncogene, 22: 3070-5, 2003.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. L. Schwartz, R. Malgor, E. Dickerson, A. T. Weeraratna, A. Slominski, J. Wortsman, N. Harii, A. D. Kohn, R. T. Moon, F. L. Schwartz, et al.
Phenylmethimazole Decreases Toll-Like Receptor 3 and Noncanonical Wnt5a Expression in Pancreatic Cancer and Melanoma Together with Tumor Cell Growth and Migration
Clin. Cancer Res., June 15, 2009; 15(12): 4114 - 4122.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Mirochnik, A. Aurora, F. T. Schulze-Hoepfner, A. Deabes, V. Shifrin, R. Beckmann, C. Polsky, and O. V. Volpert
Short Pigment Epithelial-Derived Factor-Derived Peptide Inhibits Angiogenesis and Tumor Growth
Clin. Cancer Res., March 1, 2009; 15(5): 1655 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Zhu, L. Lu, W. Cai, X. Yang, C. Li, Z. Yang, W. Zhan, J.-x. Ma, and G. Gao
Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis
Mol. Cancer Ther., December 1, 2007; 6(12): 3297 - 3306.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
C.R. Dass, T.M.N. Tran, and P.F.M. Choong
Angiogenesis Inhibitors and the Need for Anti-angiogenic Therapeutics
Journal of Dental Research, October 1, 2007; 86(10): 927 - 936.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Notari, V. Baladron, J. D. Aroca-Aguilar, N. Balko, R. Heredia, C. Meyer, P. M. Notario, S. Saravanamuthu, M.-L. Nueda, F. Sanchez-Sanchez, et al.
Identification of a Lipase-linked Cell Membrane Receptor for Pigment Epithelium-derived Factor
J. Biol. Chem., December 8, 2006; 281(49): 38022 - 38037.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. T.H. Ek, C. R. Dass, and P. F.M. Choong
Pigment epithelium-derived factor: a multimodal tumor inhibitor.
Mol. Cancer Ther., July 1, 2006; 5(7): 1641 - 1646.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Maik-Rachline and R. Seger
Variable phosphorylation states of pigment-epithelium-derived factor differentially regulate its function
Blood, April 1, 2006; 107(7): 2745 - 2752.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
D. M. Sidle, J. Maddalozzo, J. D. Meier, M. Cornwell, V. Stellmach, and S. E. Crawford
Altered Pigment Epithelium-Derived Factor and Vascular Endothelial Growth Factor Levels in Lymphangioma Pathogenesis and Clinical Recurrence
Arch Otolaryngol Head Neck Surg, November 1, 2005; 131(11): 990 - 995.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garcia, M.
Right arrow Articles by Rio, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garcia, M.
Right arrow Articles by Rio, M. D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online